2 December 2025

Notification of trade – primary insider/close associate

2 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 14 November 2025 and on 17 November 2025, regarding the commencement of the subscription period in the fully underwritten rights issue of 260,000,000 new shares in the Company (the “Rights Issue”) and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain close associates of primary insiders of the Company. Further reference is made to the stock exchange announcement published by the Company on 2 December 2025, regarding the final result of the Rights Issue and the allocation of the new shares.

2025-12-02 Allocation to PDMRs CAs

2025-12-02 PDMR - Attachment allocation of new shares

Certain primary insiders and close associates have been allocated new shares:

  • Charles Gillies O’Bryan-Tear, chairperson of the board of directors of the Company, has been allocated 2,000,000 shares.
  • Teakay Invest AS, a company closely associated to Ingrid Teigland Akay, member of the Company’s board of directors, has been allocated 664,551 shares.
  • Abakus Invest AS, a company closely associated to Øystein Soug, Chief Executive Officer of the Company, has been allocated 757,206 shares.
  • Anne Cecilie Alvik, Head of Quality Assurance, has been allocated 40,000 shares.
  • Hadean Capital I AS, a company closely associated to Ingrid Teigland Akay, member of the Company’s board of directors, has been allocated 17,787,881 shares.
  • HVentures Capital I AB, a company closely associated to Ingrid Teigland Akay, member of the Company’s board of directors, has been allocated 8,068,142 shares.
  • Olav Hellebø, member of the Company’s board of directors, has been allocated 200,000 shares.
  • Gro E. Hjellum, Chief Operating Officer, has been allocated 100,000 shares.
  • Itza AS, a company closely associated to Tore Kvam, Chief Financial Officer, has been allocated 454,324 shares.
  • Hadean Growth Fund I AS, a company closely associated to Ingrid Teigland Akay, member of the Company’s board of directors, has been allocated 8,666,991 shares.

Please refer to the attached notifications of trade for further information.

Issuance and delivery of the new shares is subject to the extraordinary general meeting of the Company to be held on 5 December 2025 approving the required share capital reduction to reduce the nominal value of the Company’s shares (as further described in section 7.4.3 of the prospectus prepared by the Company), any other resolutions required to complete the Rights Issue, and the timely payment for the new shares subscribed for and allocated.

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

 

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.  

Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close